These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 28501906)
1. Medication use for the treatment of diabetes in obese individuals. Wilding JPH Diabetologia; 2018 Feb; 61(2):265-272. PubMed ID: 28501906 [TBL] [Abstract][Full Text] [Related]
2. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Tak YJ; Lee SY Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104 [TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for obesity in individuals with type 2 diabetes. Chukir T; Shukla AP; Saunders KH; Aronne LJ Expert Opin Pharmacother; 2018 Feb; 19(3):223-231. PubMed ID: 29376439 [TBL] [Abstract][Full Text] [Related]
6. Recent advancements in drug treatment of obesity. Carter R; Mouralidarane A; Ray S; Soeda J; Oben J Clin Med (Lond); 2012 Oct; 12(5):456-60. PubMed ID: 23101148 [TBL] [Abstract][Full Text] [Related]
7. How to fight obesity with antidiabetic drugs: targeting gut or kidney? Baretić M; Troskot R Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984 [TBL] [Abstract][Full Text] [Related]
8. Drug treatment of obesity: current status and future prospects. Kakkar AK; Dahiya N Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851 [TBL] [Abstract][Full Text] [Related]
9. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Brown E; Wilding JPH; Barber TM; Alam U; Cuthbertson DJ Obes Rev; 2019 Jun; 20(6):816-828. PubMed ID: 30972878 [TBL] [Abstract][Full Text] [Related]
10. Overview of new antiobesity drugs. Hainer V Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293 [TBL] [Abstract][Full Text] [Related]
11. Review of pharmacotherapy options for the management of obesity. Bragg R; Crannage E J Am Assoc Nurse Pract; 2016 Feb; 28(2):107-15. PubMed ID: 26119641 [TBL] [Abstract][Full Text] [Related]
12. Current and emerging pharmacotherapies for obesity in Australia. Hocking S; Dear A; Cowley MA Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558 [TBL] [Abstract][Full Text] [Related]
13. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Scheen AJ; Van Gaal LF Lancet Diabetes Endocrinol; 2014 Nov; 2(11):911-22. PubMed ID: 24731666 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacological therapy of obesity]. Pagotto U; Vanuzzo D; Vicennati V; Pasquali R G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755 [TBL] [Abstract][Full Text] [Related]
15. Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. Citrome L Int J Clin Pract; 2014 Dec; 68(12):1401-5. PubMed ID: 25418525 [No Abstract] [Full Text] [Related]
16. Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States. Levin A; Kaur N; Mainoo NK; Perez A Clin Ther; 2022 Mar; 44(3):e35-e44. PubMed ID: 35105470 [TBL] [Abstract][Full Text] [Related]
17. [Cutting-edge of medicine; the prospects of novel anti-obesity drugs]. Ueno H; Nakazato M Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):753-9. PubMed ID: 24796150 [No Abstract] [Full Text] [Related]
19. Relevance of weight in the management of patients with type 2 diabetes mellitus: towards an adipocentric approach to diabetes. Gorgojo Martínez JJ Med Clin (Barc); 2016 Nov; 147 Suppl 1():8-16. PubMed ID: 28760227 [TBL] [Abstract][Full Text] [Related]